First launch for Daiichi Sankyo's oncolytic virus Delytact i...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

Daiichi Sankyo claims first okay for oncolytic virus in Japa...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malig

Sillajen explains Pexa-Vec trial failure – it was the rescue...

Immunotherapy arms race latest: Merck buys Viralytics for $3...

Merck & Co is to acquire Australian biotech Viralytics for $394 million, adding a virus-based immunotherapy to its R&D pipeline.